Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025Cancer

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJiaying LianXZXianxu ZhuangYCYing Chen

Discussion

Loading...

Member takes

Overview

Observational analysis shows Day 14 MRD predicts survival in AML patients treated with venetoclax and azacitidine, highlighting the importance of monitoring MRD and considering transplantation.

Key Points

  • Patients achieving Day 14 MRD negative had improved overall survival and event-free survival compared to MRD positive individuals.
  • Among 75 AML patients, 41.3% achieved MRD negative status while 40% did not reach complete remission.
  • Research utilized multiparametric flow cytometry to assess measurable residual disease in newly diagnosed AML patients.
  • Transplantation, along with factors like CSF3R negative status, may enhance survival outcomes in AML patients.

Cite This Study

Lian et al. (2025) studied this question.

synapsesocial.com/papers/68af63e3ad7bf08b1eae43bahttps://doi.org/10.1002/cncr.70053
View Full Paper
Ask AI
Bookmark
Share